As 'flesh-eating'Â leishmania come closer, a vaccine against them does, too
Georgia Institute of Technology Health and Medicine News Sep 25, 2017
InsectÂs habitat is expanding northward from Latin America. The outbreak regions closest to the United States of leishmaniasis have come within roughly 300 miles of the border.
No vaccine is available against Leishmania yet, but researchers have now come closer to changing that. A new experimental vaccine, made with a proprietary biological particle developed at the Georgia Institute of Technology, has immunized laboratory mice that were genetically altered to mimic the human immune system.
The vaccine exploits a weakness in LeishmaniaÂs tricky chemical camouflage, which normally hides it from the victimÂs disease-fighting cells, to trigger a forceful immune response against the parasite, according to a new study. Leishmania are the second-deadliest parasites in the world, topped only by malaria, according to the World Health Organization. There are some 30 strains of Leishmania.
ÂIf you donÂt treat it, within 20 to 40 days visceral leishmaniasis very often kills the victim, said Alexandre Marques, a professor in the parasitology department of the Universidade Federal de Minas Gerais in Brazil, and one of the lead researchers on the new experimental vaccine. Conventional treatment, though mostly effective, can leave behind small numbers of the parasite, which can lead the patient to relapse or act as a carrier, in a similar manner as malaria.
A vaccine could be better at halting or averting outbreaks.
ÂIn comparison to viruses and bacteria, these are much more complex organisms and more difficult to crack, said M. G. Finn, who also led work on the new vaccine. Finn is a professor in Georgia TechÂs School of Biological Sciences and in the School of Chemistry and Biochemistry, which he also chairs.
The new vaccine leverages intimate knowledge that MarquesÂs team has gained living and working on the edge of leishmaniasis outbreak regions. ÂAlexÂs (MarquesÂs) students collect the sand flies, then they extract the parasites in the lab and do complex mass spectrometry and other tests to study their molecular makeup in impressive detail, Finn said.
The team has uncovered minute details on the outer surface of Leishmania that make it vulnerable to a human immune reaction. The potential new vaccine, invented at Georgia Tech, employs a fake virus as bait to attract major immune system forces to these weaknesses to attack them.
The fake virus, or virus-like particle, is not infectious, and the body destroys it after use. FinnÂs lab has developed many variations of such particles in recent years, and other products containing it have already been through phase II human clinical trials.
Marques and Finn published the results of their vaccination development and testing on September 13, 2017, in the journal ACS Central Science.
Go to Original
No vaccine is available against Leishmania yet, but researchers have now come closer to changing that. A new experimental vaccine, made with a proprietary biological particle developed at the Georgia Institute of Technology, has immunized laboratory mice that were genetically altered to mimic the human immune system.
The vaccine exploits a weakness in LeishmaniaÂs tricky chemical camouflage, which normally hides it from the victimÂs disease-fighting cells, to trigger a forceful immune response against the parasite, according to a new study. Leishmania are the second-deadliest parasites in the world, topped only by malaria, according to the World Health Organization. There are some 30 strains of Leishmania.
ÂIf you donÂt treat it, within 20 to 40 days visceral leishmaniasis very often kills the victim, said Alexandre Marques, a professor in the parasitology department of the Universidade Federal de Minas Gerais in Brazil, and one of the lead researchers on the new experimental vaccine. Conventional treatment, though mostly effective, can leave behind small numbers of the parasite, which can lead the patient to relapse or act as a carrier, in a similar manner as malaria.
A vaccine could be better at halting or averting outbreaks.
ÂIn comparison to viruses and bacteria, these are much more complex organisms and more difficult to crack, said M. G. Finn, who also led work on the new vaccine. Finn is a professor in Georgia TechÂs School of Biological Sciences and in the School of Chemistry and Biochemistry, which he also chairs.
The new vaccine leverages intimate knowledge that MarquesÂs team has gained living and working on the edge of leishmaniasis outbreak regions. ÂAlexÂs (MarquesÂs) students collect the sand flies, then they extract the parasites in the lab and do complex mass spectrometry and other tests to study their molecular makeup in impressive detail, Finn said.
The team has uncovered minute details on the outer surface of Leishmania that make it vulnerable to a human immune reaction. The potential new vaccine, invented at Georgia Tech, employs a fake virus as bait to attract major immune system forces to these weaknesses to attack them.
The fake virus, or virus-like particle, is not infectious, and the body destroys it after use. FinnÂs lab has developed many variations of such particles in recent years, and other products containing it have already been through phase II human clinical trials.
Marques and Finn published the results of their vaccination development and testing on September 13, 2017, in the journal ACS Central Science.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries